Amelanotic primary cervical malignant melanoma:A case report and review of literature

作     者：Jin-Lin Duan Jing Yang Yong-Long Zhang Wen-Tao Huang 

作者机构：Department of PathologyThe Affiliated Tongren HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200332China Laboratory of Targeted Therapy and Precision MedicineDepartment of Clinical LaboratoryShanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai 200233China 

出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)

年 卷 期：2024年第15卷第7期

页      面：953-960页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by the National Natural Science Foundation of China,No.82073258 the Excellent Youth Program of Shanghai Jiao Tong University Affiliated Sixth People's Hospital,No.ynyq202105 the Research Fund of Shanghai Tongren Hospital,Shanghai Jiao Tong University School of Medicine,No.TRYJ201702 Start-up Funding for Talent Introduction,Shanghai Tongren Hospital,Shanghai Jiao Tong University School of Medicine,No.TR2020rc04 Special Project of Medical and Health Research in Changning District,Shanghai,No.CNKW2017Y09 

主　　题：Primary cervical malignant melanoma MelanA Immunotherapy Patient management Case report 

摘      要：BACKGROUND Primary malignant melanoma of the cervix(PMMC)is an extremely rare disease that originates from primary cervical malignant melanoma and frequently re-presents a challenge in disease diagnosis due to unclarified clinical and histo-logical presentations,particularly those without *** SUMMARY Here,we report a case of amelanotic PMMC,with a history of breast cancer and thyroid *** patient was finally diagnosed by immunohistochemical staining and staged as IB2 based on the International Federation of Gynecology and Obstetrics with reference to National Comprehensive Cancer Network guide-lines and was treated with radical hysterectomy,bilateral salpingo-oophorectomy and pelvic *** then received combination therapy consisting of immunotherapy with tislelizumab and radiofrequency *** has remained free of disease for more than 1 *** The differential diagnosis process reenforced the notion that immunohisto-chemical staining is the most reliable approach for amelanotic PMMC *** to the lack of established therapeutic guidelines,empirical information from limited available studies does not provide the rationale for treatment-decision *** integrating omics technologies and patient-derived xenografts or mini-patient-derived xenograft models this will help to identify selective thera-peutic window(s)and screen the appropriate therapeutics for targeted therapies,immune checkpoint blockade or combination therapy strategies effectively and precisely that will ultimately improve patient survival.